Sep 24, 2026 · 5 min
AI optimism lifts Everpure as biotech financing rattles Viking
Stitch Fix Earnings; Everpure Soars; Viking Therapeutics Falls
The episode shows how markets are rewarding long-term AI infrastructure demand while punishing near-term uncertainty and dilution risk.
- 1Stitch Fix shares fell after mixed quarterly results and a weaker full-year EBITDA outlook.
- 2Everpure rallied on a strong 2028 revenue forecast tied to AI and hyperscaler demand.
- 3Viking Therapeutics declined after announcing roughly $500 million in stock and convertible-debt financing.
Don't miss
Everpure’s upbeat 2028 revenue forecast stands out as the episode’s clearest example of investors rewarding AI and hyperscaler exposure.
The brief
As equities pull back, Bloomberg’s Stock Movers Report tracks three sharply different reactions: Stitch Fix falls, Everpure rallies and Viking Therapeutics slides.
Stitch Fix’s mixed quarterly results and weaker-than-expected full-year EBITDA outlook put pressure on the online styling company and its stock.
Everpure moves the other way after offering an upbeat 2028 revenue forecast, with AI and hyperscaler demand supplying the growth story.
Viking Therapeutics faces a different problem: its shares fall after the company announces roughly $500 million in stock and convertible-debt offerings.
Together, the moves show investors separating credible long-term infrastructure demand from disappointing guidance and the dilution risk of new financing.
Featuring
Stitch Fix
P
Viking Therapeutics
Bloomberg L.P.Listen to the full episode and explore every guest, topic, and moment on PodLume.